Arcadia Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Arcadia Biosciences Inc RKDA.OQ reported a quarterly adjusted loss of $2.99​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-2.52. The lone analyst forecast for the quarter was for a loss of 89 cents per share.

• Revenue rose 3.9% to $1.22 million from a year ago; analysts expected $1.20 million.

• Arcadia Biosciences Inc's reported EPS for the quarter was a loss of $2.99​.

• The company reported a quarterly loss of $4.06 million.

• Arcadia Biosciences Inc shares had fallen by 42.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 28.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the food processing peer group is also "buy"

Wall Street's median 12-month price target for Arcadia Biosciences Inc is $12.00

This summary was machine generated from LSEG data March 20 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING	ESTIMATE	ACTUAL	BEAT, MET, MISSED
Dec. 31 2024	-0.89	-2.99	Missed
Sep. 30 2024	-0.81	-1.18	Missed
Jun. 30 2024	1.55	0.78	Missed
Mar. 31 2024	-2.21	-1.78	Beat